Latest News
vTv Therapeutics Inc.
- vTv Therapeutics Inc. Estimates – NASDAQ:VTVT
- vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program - Slideshow (NASDAQ:VTVT) 2026-10-21
- vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia
- vTv Therapeutics (Nasdaq:VTVT) - Stock Analysis
- Millennium Management LLC Expands Stake in vTv Therapeutics Inc (VTVT) with 72,607-Share Purchase
- vTv Therapeutics (VTVT) Highlights Hypoglycemia Burden in T1D Ad
- vTv Therapeutics stock jumps on FDA orphan drug status
- Three parties report shared voting power over vTv Therapeutics (VTVT) shares in a passive stake amendment.
- FDA grants orphan drug status to vTv Therapeutics' sickle cell drug
- vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
- vTv Therapeutics Announces Completion of Enrollment in
- vTv Therapeutics completes Phase 3 enrollment for T1D drug By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →